Sign in
WithdrawnPhase 1/2

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

Key facts

Who runs it
Naoyuki G. Saito, M.D., Ph.D.
Where
Indianapolis, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
Oct 2023
Expected to end
Apr 2029
Type of study
Interventional
Treatments tested
  • Fludarabine + Total Marrow Irradiation
Record updated
11 December 2023
Why it stopped
insufficient staff and updates in standard practice have made it difficult to recruit participants

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Documentation of Disease: Patients must be diagnosed with one of the following conditions:; Acute Myeloid Leukemia (AML), with no history of extramedullary disease, who are not in complete remission, who have either primary refractory or relapsed disease, and who do not have more than one of the following adverse factors:; Duration of first CR < 6 months (if previously in CR), based on the best overall clinical assessment of the disease course, not solely based on blood test or bone marrow biopsy results; Poor risk karyotype including any of the following: complex karyotype with ≥3 clonal abnormalities, 5q-/-5, 7q-/-7, 11q23 abnormalities, inv(3q), 20q or 21q abnormalities, t (6;9), t (9;22), 17p abnormalities [or TP53 mutations] or monosomal karyotype. Molecular typing (except for TP53 mutation) will not be used for eligibility criteria determination; Circulating peripheral blood blasts at time of enrollment; Karnofsky performance status <90%; Acute Lymphocytic Leukemia (ALL) who are not in complete remission, who have either primary refractory or relapsed disease, and who do not have more than one of the following adverse factors:; Primary refractory or first relapse. Patients in second or subsequent relapse are excluded; Bone marrow blasts >25% within 30 days before the start of the conditioning regimen; Age >40 years; Myelodysplasia with a Revised International Prognostic Score (IPSS-R) of greater than 4.5 (i.e., high- or very-high risk); Chronic Myelogenous Leukemia (CML) in accelerated phase, defined by any of the following:; 10-19% blasts in peripheral blood white cells or bone marrow; Peripheral blood basophils at least 20%; Persistent thrombocytopenia (< 100 x 109/l) unrelated to therapy, or persistent thrombocytosis (>1000 x 109/l) unresponsive to therapy; Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy; Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase)
  • The patient must be 18-65 years old at time of consent
  • Signed written informed consent: Patient must be capable of understanding the investigational nature of this study, potential risks and benefits of the study, and be able to provide a valid informed consent
  • Availability of a consenting human leukocyte antigens (HLA)-matched donor
  • Karnofsky Performance Status 70% or higher
  • Required baseline laboratory values:; Estimated creatinine clearance ≥ 60 ml/min; Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal value; Bilirubin ≤ 1.5 x upper limit of normal value (unless determined to be related to Gilbert's disease)
  • Required baseline cardiac function values:; Required baseline cardiac function of left ventricular ejection fraction (LVEF) > 45 % corrected
  • Required baseline pulmonary function values:; Required baseline pulmonary function of lung diffusing capacity (DLCO) > 45 % predicted (corrected for hemoglobin))

Who cannot take part

  • Prior radiation therapy
  • Patients who have had a prior autologous or allogeneic bone marrow or stem cell transplantation
  • Gemtuzumab ozogamicin (trade name: Mylotarg) and/or inotuzumab ozogamicin (trade name: Besponsa) use within 60 days before start of the conditioning regimen
  • Though this is NOT an exclusion criterion, we strongly recommend discontinuation of any steroidal oral contraceptives at least 7 days before start of the conditioning regimen. Use of therapeutic alternatives, including leuprolide should be considered to reduce the risk of SOS/VOD. Of note, for patients already on steroidal oral contraceptives for excessive menorrhagia, the switch to leuprolide should occur at least 2 weeks before the start of the conditioning regimen
  • HIV seropositive patients
  • Pregnant or nursing females

Where in United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, United States

About the trial

What the trial wants to find out

This is a phase I/II clinical trial to determine the maximum tolerated dose (MTD) of total marrow irradiation (TMI) followed by fludarabine in the context of a myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as well as to determine the efficacy of the regimen in patients with high-risk leukemia and myelodysplasia.

The group in the trial

  • Fludarabine + Total Marrow IrradiationTreatment being tested

    Fludarabine will be administered sequentially after the administration of TMI. TMI will be delivered on Days -11, -10, -9, -8, and -7 (1.4-2.2 gray (GY)/fraction, twice a day) followed by fludarabine on Days -6, -5, -4, -3, and -2 (150 mg/m2, 30 mg/m2/day)

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
11 December 2023